<SEC-DOCUMENT>0001299933-11-003397.txt : 20111122
<SEC-HEADER>0001299933-11-003397.hdr.sgml : 20111122
<ACCEPTANCE-DATETIME>20111121182522
ACCESSION NUMBER:		0001299933-11-003397
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20111115
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111122
DATE AS OF CHANGE:		20111121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		111220058

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_43575.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Cumberland Pharmaceuticals Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	November 15, 2011
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Cumberland Pharmaceuticals Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33637
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	62-1765329
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	2525 West End Avenue, Suite 950, Nashville, Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	37203
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(615) 255-0068
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 1.01 Entry into a Material Definitive Agreement.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
Effective November 15, 2011, we entered into an agreement with Mylan Inc., or Mylan, to acquire the worldwide rights to certain assets and the FDA registration related to the Kristalose&#174; brand, collectively the Mylan Agreement.  As consideration for the assets, we will pay to Mylan royalties based on future sales of Kristalose&#174;.<br><br>As previously disclosed in certain our of prior SEC filings, prior to the acquisition of these assets, we had executed an agreement with Inalco S.p.A and Inalco Biochemicals, Inc., collectively Inalco, for exclusive distribution and marketing rights in addition to an exclusive license regarding the intellectual property for Kristalose&#174; , or the Kristalose Agreement. As a condition precedent to the acquisition of the worldwide rights discussed above, Mylan acquired certain rights to Kristalose&#174; from Inalco.  Therefore, along with Inalco, we terminated the Kristalose Agreement on November 15, 2011 concurrently with the entry into the Mylan Agreement. We incurred no early termination penalties upon termination of the Kristalose Agreement.  The foregoing description of the Kristalose Agreement is qualified in its entirety by Exhibits 10.9, 10.9.1, 10.9.2, 10.9.3, and 10.9.4 to the Company&#x2019;s Annual Report on Form 10-K filed on March 11, 2011. <br><br>The Mylan Agreement is attached hereto as Exhibit 10.28, and the foregoing summary is qualified in its entirety by such agreement.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 1.02 Termination of a Material Definitive Agreement.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
The disclosures included in Item 1.01 of this Form 8-K are hereby incorporated by reference into this Item 1.02.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
d)  <br><br>10.28&#x2020;     Asset Purchase and Royalty Agreement for Kristalose dated November 15, 2011 by and between Mylan Inc. and Cumberland Pharmaceuticals Inc.<br><br><br>&#x2020; Confidential treatment has been requested for portions of this exhibit.  These portions have been omitted from Exhibit 10.28 and submitted separately to the Securities and Exchange Commission.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	November 21, 2011
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Rick S. Greene
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Rick S. Greene
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	10.28
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Asset Purchase and Royalty Agreement for Kristalose dated November 15, 2011 by and between Mylan Inc. and Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-10.28 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="right" style="font-size: 10pt"><FONT style="font-size: 12pt"><B>EXHIBIT 10.28</B></FONT>



<P align="center" style="font-size: 12pt">*Certain portions of this exhibit have been omitted pursuant to a request for confidential<BR>
treatment which has been filed separately with the SEC.



<P align="center" style="font-size: 12pt"><U><B>ASSET PURCHASE AND ROYALTY AGREEMENT</B></U>



<P align="left" style="font-size: 12pt; text-indent: 4%"><B>THIS ASSET PURCHASE AND ROYALTY AGREEMENT </B>(this &#147;Agreement&#148;), is hereby entered into as of the
15<sup>th</sup> day of November, 2011 (the &#147;Effective Date&#148;) by and between Mylan Inc., a
Pennsylvania corporation located at 1500 Corporate Drive, Canonsburg, Pennsylvania 15317 (&#147;Mylan&#148;)
and Cumberland Pharmaceuticals Inc., a corporation organized under the laws of the State of
Tennessee with a place of business at 2525 West End Avenue, Suite&nbsp;950, Nashville, Tennessee, USA
37203 (hereinafter referred to as &#147;Cumberland&#148;). Mylan</FONT><FONT style="font-size: 11pt"> </FONT><FONT style="font-size: 12pt">and Cumberland may each be
referred to herein individually as a &#147;Party&#148; and collectively as the &#147;Parties.&#148;
</FONT>

<P align="center" style="font-size: 12pt"><B>W I T N E S S E T H:</B>



<P align="left" style="font-size: 12pt; text-indent: 4%"><B>WHEREAS</B>, Mylan, has negotiated for the acquisition of certain assets related to the Product
(as defined below), from Inalco S.p.A. pursuant to certain terms of an asset purchase agreement by
and between Mylan Inc., Mylan Institutional Inc., (formerly known as UDL Laboratories, Inc.),
Inalco S.p.A. and Inalco Biochemicals, Inc. dated as of March&nbsp;31, 2011 (&#147;Inalco Asset Purchase
Agreement&#148;) and this Agreement is conditional upon the successful acquisition of such assets by
completing the closing anticipated by the Inalco Asset Purchase Agreement;


<P align="left" style="font-size: 12pt; text-indent: 4%"><B>WHEREAS, </B>Mylan wishes to assign such assets and rights to Cumberland, and Cumberland desires
to so acquire those assets and rights, all upon the terms of this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%"><B>WHEREAS</B>, Cumberland, Inalco S.p.A. and Inalco Biochemicals, Inc. are parties to the Kristalose
Agreement dated as of April, 2006 (the &#147;Kristalose Agreement&#148;) which will be terminated and this
Agreement is conditional upon the termination of the Kristalose Agreement;


<P align="left" style="font-size: 12pt; text-indent: 4%"><B>NOW, THEREFORE</B>, in consideration of the foregoing premises and of the representations,
warranties, covenants and agreements herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto,
intending to be legally bound, agree as follows:


<P align="center" style="font-size: 12pt"><B>ARTICLE 1<BR>
DEFINITIONS AND CONSTRUCTION</B>



<P align="left" style="font-size: 12pt; text-indent: 6%">1.1 <U>Definitions</U>. Whenever used in this Agreement, unless otherwise clearly indicated
by the context, the terms defined below shall have the indicated meanings. Other terms may be
defined elsewhere in the text of this Agreement and, unless otherwise indicated, shall have such
meaning throughout this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Affiliate</U>&#148; means with respect to a Party, a Person that controls, is controlled by or
is under common control with such Party. For the purposes of this definition, the word &#147;control&#148;
(including, with correlative meaning, the terms &#147;controlled by&#148; or &#147;under common control with&#148;)
means the actual power, either directly or indirectly through one or more intermediaries, to direct
the management and policies of such Person, whether by the ownership of fifty percent (50%) or more
of the voting stock of such Person (it being understood that the direct or indirect ownership of a
lesser percentage of such stock shall not necessarily preclude the existence of control), or by
contract or otherwise.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Agreement</U>&#148; shall have the meaning set forth in the Preamble of this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Aggrieved Party</U>&#148; shall have the meaning set forth in Section&nbsp;8.2(a).


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>ANDA</U>&#148; means an abbreviated new drug application filed with the FDA pursuant to 21
U.S.C. &#167; 355(j) and 21 C.F.R. &#167; 314.3.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Applicable Laws</U>&#148; means all laws, statutes, regulations, rules, guidelines, ordinances
or the like of any Governmental Authority having jurisdiction over, or applicable to, the Purchased
Assets or a Party in connection with its obligations under this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Assumed Liabilities</U>&#148; means liabilities related to the Purchased Assets, the purchase
or use thereof, and the sale of the Product; <U>provided</U>, <U>however</U>, that &#147;Assumed
Liabilities&#148; shall not include any Excluded Liabilities.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Books and Records</U>&#148; means all books and records in the possession of Mylan and its
Affiliates specifically related to the Manufacture, testing, use or sale of the Product.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Business Day</U>&#148; means any day other than a Saturday, a Sunday or a day on which banks
in New York City, New York are authorized or obligated by law or executive order to not open or
remain closed.


<P align="left" style="font-size: 12pt; text-indent: 4%"><U>&#147;Calendar Quarter&#148;</U> shall mean each three (3)&nbsp;month period ending March&nbsp;31, June&nbsp;30,
September&nbsp;30, and December&nbsp;31.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Claim</U>&#148; shall have the meaning set forth in Section&nbsp;8.2(a).


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Closing</U>&#148; shall have the meaning set forth in Section&nbsp;3.1.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Closing Date</U>&#148; shall have the meaning set forth in Section&nbsp;3.1.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Confidential Information</U>&#148; means, with respect to a Party (such Party, the
&#147;<U>Disclosing Party</U>&#148;), all non-public information of any kind whatsoever (including data,
software, materials, compilations, formulae, models, patent disclosures, procedures, processes,
projections, protocols, results of experimentation and testing, specifications, strategies, and
techniques), and all tangible and intangible embodiments thereof of any kind whatsoever (including
materials, samples, apparatus, compositions, documents, drawings, machinery, patent applications,
records and reports), that are disclosed by or on behalf of the Disclosing Party to the other Party
or its Affiliates or Representatives (such other Party, the &#147;<U>Receiving Party</U>&#148;), including
any and all copies, replications or embodiments thereof. The Confidential Information included
within the Purchased Assets, as acquired by Cumberland pursuant to this Agreement (to the extent
relating solely to the Purchased Assets and not to any other business, asset or activity of Mylan
or its Affiliates, including, with respect to the Excluded Assets), shall, immediately following
the Closing, be the Confidential Information of Cumberland, and Cumberland shall be deemed the
Disclosing Party and Mylan and its Affiliates the Receiving Party of such Confidential Information
regardless of the origination of such Confidential Information. Confidential Information of a
Disclosing Party shall not include information that the Receiving Party can establish by competent
proof (a)&nbsp;to have been publicly known prior to disclosure of such information by the Disclosing
Party to the Receiving Party, as evidenced by written records or similar proof, (b)&nbsp;to have become
publicly known, without fault on the part of the Receiving Party, subsequent to disclosure of such
information by the Disclosing Party to the Receiving Party, as evidenced by written records or
similar proof, (c)&nbsp;to have been received by the Receiving Party free of an obligation of
confidentiality from a source rightfully having possession of and the right to disclose such
information free of an obligation of confidentiality, as evidenced by written records or similar
proof, (d)&nbsp;to have been otherwise known by the Receiving Party free of an obligation of
confidentiality prior to disclosure of such information by the Disclosing Party to the Receiving
Party, as evidenced by written records or similar proof, or (e)&nbsp;to have been independently
developed by employees or agents of the Receiving Party without the use of Confidential Information
of the Disclosing Party, as evidenced by written records or similar proof.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Cumberland</U>&#148; shall have the meaning set forth in the Preamble of this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Cumberland Deliverables</U>&#148; shall have the meaning set forth in Section&nbsp;3.1.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Encumbrances</U>&#148; means all encumbrances of any kind, including security interests,
liens, pledges, claims, charges, equitable interests, hypothecations, mortgages, options, licenses,
assignments, powers of sale, retentions of title, rights of pre-emption, rights of first refusal,
restrictions on transferability or defects of title, but expressly excluding the FDA Letter.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Excluded Asset</U>&#148; means any asset, interest, right or claim of Mylan that is not
included in the definition of Purchased Assets, including any of the following:


<P align="left" style="font-size: 12pt; text-indent: 8%">(a)&nbsp;(i)&nbsp;the name &#147;Mylan&#148; and any and all variations, formatives and derivatives thereof, all
composite marks including such names or any such formatives or derivatives and any colorable
imitation of any of the foregoing, (ii)&nbsp;all trademarks, trade names, brand names, logotypes,
symbols, service marks, and the goodwill of the business symbolized thereby, including
registrations and applications for registrations thereof and all renewals, modifications and
extensions thereof, currently used or proposed to be used by Mylan or any of its Affiliates in
connection with the manufacture, marketing, sale and distribution of the Product or any other
products, (iii)&nbsp;except as expressly set forth in this Agreement, any intellectual property related
to the Manufacturing, marketing, use, sale or distribution of the Product in the Territory, and
(iv)&nbsp;any computer programs and software;


<P align="left" style="font-size: 12pt; text-indent: 8%">(b)&nbsp;any administrative, financial and accounting records;


<P align="left" style="font-size: 12pt; text-indent: 8%">(c)&nbsp;Any inventory unrelated to the Product, and any Product Inventory which Cumberland does
not choose to purchase in this transaction.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Excluded Liabilities</U>&#148; means </FONT><FONT style="font-size: 11.5pt">all Liabilities related to the Purchased Assets or
the Product which arise or become due prior to the Closing Date.
</FONT>

<P align="left" style="font-size: 11.5pt; text-indent: 4%"><FONT style="font-size: 12pt">&#147;<U>FDA</U>&#148; means the United States Food and Drug Administration, and any successor
agency thereto.
</FONT>

<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>FDA Letter</U>&#148; means the letter attached hereto as Exhibit&nbsp;B duly executed by an
authorized officer of Mylan notifying the FDA of the transfer of the Product ANDA to Cumberland.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>General Assignment and Bill of Sale</U>&#148; means the General Assignment and Bill of Sale
attached hereto as Exhibit&nbsp;A.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Governmental Authority</U>&#148; or &#147;<U>Governmental Authorities</U>&#148; means any national,
foreign, federal, state or local judicial, legislative, executive, administrative or regulatory
body or authority, or its equivalent, including the FDA.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Indemnifying Party</U>&#148; shall have the meaning set forth in Section&nbsp;8.2(a).


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Intellectual Property</U>&#148; means all (a)&nbsp;Patents, (b)&nbsp;copyrightable works, copyrights in
works of authorship of any type, including computer software and industrial designs, registrations
and applications for registration thereof, (c)&nbsp;trade secrets, Know-How and other material
confidential or proprietary technical, business and other information necessary to Manufacture,
test, use or sell the Product, and all rights in any jurisdiction to limit the use or disclosure
thereof, (d)&nbsp;any and all rights of application regarding any of the foregoing including with
respect to extensions and the like, and (e)&nbsp;rights to sue and recover damages or obtain injunctive
relief for past, present and future infringement, dilution, misappropriation, violation or breach
thereof.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Know-How</U>&#148; means any and all product specifications, processes, product designs,
Manufacturing information, engineering and other manuals and drawings, standard operating
procedures, flow diagrams, chemical, pharmacological, toxicological, pharmaceutical, physical and
analytical, safety, quality assurance, quality control and clinical data, technical information,
data, research records and similar data and information.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Liabilities</U>&#148; means any and all liabilities and obligations, whether accrued or fixed,
absolute or contingent, matured or unmatured, or determined or determinable, including those
arising under any Applicable Law, action or governmental order and those arising under any
contract, agreement, arrangement, commitment or undertaking, or otherwise.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Losses</U>&#148; means any and all Liabilities, losses, judgments, assessments and damages
paid or payable to a Third Party in connection with a Claim including all related costs and
expenses, including reasonable attorneys&#146; fees and costs of defending against lawsuits, complaints,
actions or other litigation; provided, however, that payments in settlement of a Claim shall only
be included to the extent approval of the settlement was provided in accordance with Article&nbsp;8.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Manufacture/Manufacturing/Manufactured</U>&#148; means all operations in the acquisition of
materials for, and the production, packaging, labeling and quality control and release testing or
other analysis of the Product and the associated ingredients and components.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Mylan</U>&#148; shall have the meaning set forth in the Preamble of this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Mylan Deliverables</U>&#148; shall have the meaning set forth in Section&nbsp;3.1.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>NDC</U>&#148; means national drug code, as filed with or accepted by the FDA.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Net Sales</U>&#148; means the gross invoice price from sales of the Product in the Territory
by Cumberland or its Affiliates, less standard and customary allowances for:


<P align="left" style="font-size: 12pt; text-indent: 8%">(a)&nbsp;returns and discounts, including, discounts made by means of rebates, to direct or
indirect customers, or chargebacks directly related to sales of such Finished Product (and
including rebates or other payments required to be paid to governmental entities in connection with
sales of such product pursuant to the Omnibus Budget Reconciliation Act of 1990 and similar or
other Federal or state legislation or programs) including for damaged goods, returns, recalls,
rebates or rejections;


<P align="left" style="font-size: 12pt; text-indent: 8%">(b)&nbsp;applicable taxes (to the extent borne by Cumberland or its Affiliates and separately
stated on the invoice and included in the gross invoice price), other than income taxes;


<P align="left" style="font-size: 12pt; text-indent: 8%">(c)&nbsp;sales credits customary in the industry and accrued in accordance with applicable
Accounting Standards, including price protection, shelf stock adjustments and other price
adjustments; re-procurement charges by customers (backorder charges) and other similar charges; and


<P align="left" style="font-size: 12pt; text-indent: 8%">(d)&nbsp;any other specifically identifiable costs or charges included in the gross invoice price
for the finished Products customarily deducted in the pharmaceutical industry.


<P align="left" style="font-size: 12pt; text-indent: 8%">Net Sales shall be determined from Cumberland&#146;s or its Affiliates&#146; books and records kept in
accordance with Accounting Standards, subject to periodic true-ups based on actuals.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Party</U>&#148; and &#147;<U>Parties</U>&#148; shall have the meaning set forth in the Preamble of this
Agreement.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Patents</U>&#148; means all patents, patent applications including provisional applications
and statutory invention registrations, including reissues, divisions, continuations,
continuations-in-part, and reexaminations, all inventions disclosed therein, all rights therein
provided by international treaties and conventions, together with all applicable foreign
counterpart patents and patent applications, and all rights to obtain patents and registrations
thereto, as well as any extensions, supplementary protection certificates or the like applicable to
any and all of the foregoing. For the avoidance of doubt, Cumberland shall have the right to seek
Patent rights worldwide.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Person</U>&#148; means an individual, a corporation, a limited liability company, a
partnership, an association, a trust or other entity or organization, including a government or
political subdivision or an agency or instrumentality thereof.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Product</U>&#148; means lactulose crystals with the label and packaged in 10-gram and 20-gram
pouches and all other strengths and dosage forms sold under the Kristalose Trademark
(&#147;Kristalose&#148;). For the avoidance of doubt, Cumberland shall have the right to seek approval by
any applicable Regulatory Authority worldwide.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Product ANDA</U>&#148; means Lactulose United States ANDA No.&nbsp;074712 and any supplements and
amendments thereto.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Product Know-How</U>&#148; means any Know-How specifically related to and necessary for the
Manufacture, testing, use or sale of the Product, as set forth in the Product ANDA.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Product Intellectual Property</U>&#148; means the Intellectual Property owned or controlled by
Mylan and directly related to the Product, including the Product Know-How.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Product Regulatory Files</U>&#148; means all Regulatory Files and Regulatory Approvals owned
or controlled by Mylan and/or its Affiliates as of the Closing Date related specifically to the
Manufacture, testing, use or sale of the Product, including the Product ANDA in the Territory.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Purchased Assets</U>&#148; means: Mylan transfers to Cumberland full, worldwide rights to the
intellectual property rights, know-how, labels, and trademarks, including but not limited to:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the United States Registered Trademark KRISTALOSE, Registration
No.&nbsp;2,439,494 and Trademark Additional Rights;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Product ANDA;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other rights in the applicable trademarks, trademark
applications and registrations, trade names, trade dresses, service logos, and
other designations of origin;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Product Intellectual Property;</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all Product Regulatory Files; and</TD>
</TR>

</TABLE>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all Books and Records</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 12pt; text-indent: 8%">provided, however, that the Purchased Assets shall not include any of the assets, rights and
claims defined as Excluded Assets hereunder.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Regulatory Approval</U>&#148; means any and all approvals, licenses, registrations or
authorizations of the applicable Regulatory Authority necessary for the marketing of the Product in
the Territory.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Regulatory Authority</U>&#148; means any Governmental Authority whose approval is necessary to
develop, Manufacture, import, and/or market the Product in the Territory.


<P align="left" style="font-size: 12pt">&#147;<U>Regulatory Files</U>&#148; means:


<P align="left" style="font-size: 12pt; text-indent: 6%">(a)&nbsp;the technical, medical and scientific licenses, permits, registrations, authorizations and
approvals (including applications therefor, supplements and amendments, pre- and post-approvals,
and labeling approvals) of any Governmental Authority necessary for the development (including the
conduct of clinical trials), Manufacture, distribution, marketing, promotion, offer for sale,
import, export or sale of a drug product or a drug substance;


<P align="left" style="font-size: 12pt; text-indent: 6%">(b)&nbsp;all technical, scientific, chemical, biological, pharmacological, and toxicological data
as well as all clinical and preclinical reports (together with clinical data sets associated with
such reports), and all validation documents and data; and


<P align="left" style="font-size: 12pt; text-indent: 6%">(c)&nbsp;all correspondence to or from Governmental Authorities.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Representatives</U>&#148; of a Party means such Party&#146;s officers, directors, employees,
agents, consultants, advisors, or other representation, including legal counsel, accountants and
financial advisors.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Royalty</U>&#148; shall have the meaning set forth in Article&nbsp;4.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Territory</U>&#148; shall mean any country where the Product may be lawfully sold including,
without limitation, The United States of America, its territories and possessions. For the
avoidance of doubt, Cumberland shall have the right to seek approval by any applicable Regulatory
Authority worldwide.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Third Party</U>&#148; means any entity other than Mylan, Cumberland and their respective
Affiliates.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Trademark</U>&#148; means United States Registered Trademark KRISTALOSE, Registration No.
2,439,494 or any subsequent registration of the mark KRISTALOSE in the Territory. For the
avoidance of doubt, Cumberland shall have the right to seek Trademark rights worldwide.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Trademark Additional Rights</U>&#148; means other rights in the applicable trademarks,
trademark applications and registrations, trade names, trade dresses, service logos, and other
designations of origin.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Trademark Assignment Agreement &#150; 2011</U>&#148; means the agreement attached hereto as Exhibit
C duly executed by and between the Parties assigning the Trademark from Mylan to Cumberland.


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Transaction Agreements</U>&#148; means this Agreement and the Trademark Assignment Agreement &#150;
2011, the General Assignment and Bill of Sale, together, and each, individually, a &#147;Transaction
Agreement.&#148;


<P align="left" style="font-size: 12pt; text-indent: 4%">&#147;<U>Year</U>&#148; shall mean the twelve (12)&nbsp;month period commencing on the Effective Date and
each twelve (12)&nbsp;month period beginning on the anniversary thereof.



<P align="left" style="margin-left:2%; font-size: 12pt; text-indent: 4%">1.2 <U>Interpretation and Construction; Currency</U>.


<P align="left" style="font-size: 12pt; text-indent: 10%">(a)&nbsp;Unless the context of this Agreement otherwise requires, (i)&nbsp;the terms &#147;include,&#148;
&#147;includes,&#148; or &#147;including&#148; shall be deemed to be followed by the words &#147;without limitation&#148; unless
otherwise indicated; (ii)&nbsp;the terms &#147;hereof,&#148; &#147;herein,&#148; &#147;hereby,&#148; and derivative or similar words
refer to this entire Agreement; and (iii)&nbsp;the terms &#147;Article,&#148; &#147;Section&#148; and &#147;Exhibit&#148; refer to the
specified Article, Section and Exhibit of this Agreement. Whenever this Agreement refers to a
number of days, unless otherwise specified, such number shall refer to calendar days. The headings
and paragraph captions in this Agreement are for reference and convenience purposes only and shall
not affect the meaning or interpretation of this Agreement. This Agreement shall not be
interpreted or construed in favor of or against either Party because of its effort in preparing it.


<P align="left" style="font-size: 12pt; text-indent: 10%">(b)&nbsp;All payments to be made by Cumberland to Mylan under this Agreement shall be made in
United States dollars and may be paid by check made to the order of Mylan or bank wire transfer in
immediately available funds to such bank account in the United States as may be designated in
writing by Mylan from time to time.


<P align="center" style="font-size: 12pt"><B>ARTICLE 2<BR>
PURCHASE AND SALE</B>




<P align="left" style="margin-left:2%; font-size: 12pt; text-indent: 4%">2.1 <U>Purchase and Sale</U>.


<P align="left" style="font-size: 12pt; text-indent: 10%">(a)&nbsp;On the terms and subject to the conditions set forth in this Agreement, on the Closing
Date, Mylan shall sell, assign, transfer and deliver to Cumberland, and Cumberland shall purchase
from Mylan, all of Mylan&#146;s rights and interest in and to the Purchased Assets, free and clear of
any Liens, and Cumberland will assume the Assumed Liabilities.


<P align="center" style="font-size: 12pt"><B>ARTICLE 3<BR>
THE CLOSING</B>



<P align="left" style="font-size: 12pt; text-indent: 6%">3.1 <U>The Closing</U>. The closing of the Transaction Agreements (the &#147;<U>Closing</U>&#148;)
shall take place as shall be agreed upon in writing by Cumberland and Mylan on the date hereof or
such other date, time and place as shall be agreed upon in writing by Cumberland and Mylan on or
before Sixty (60)&nbsp;days from the Effective Date of this Agreement (the actual date and time being
herein called the &#147;<U>Closing Date</U>&#148;). The Closing shall be deemed effective as of 12:01&nbsp;a.m.
on the Closing Date.3.2 <U>Deliveries by Mylan</U>. At the Closing, Mylan shall deliver or cause
to be delivered to Cumberland copies of the Product Regulatory Files, copies of any Books and
Records, the duly executed General Assignment and Bill of Sale, all information and materials in
Mylan&#146;s possession and/or control that is necessary for Cumberland to assume regulatory
responsibilities for the Product (and not otherwise provided by Mylan to Cumberland as part of the
Purchased Assets) (collectively, the &#147;<U>Mylan Deliverables</U>&#148;).3.3 <U>Deliveries by
Cumberland</U>. At the Closing, Cumberland shall deliver, or cause to be delivered, to Mylan the
duly executed General Assignment and Bill of Sale, Trademark Assignment Agreement &#150; 2011
(collectively, the &#147;<U>Cumberland Deliverables</U>&#148;).


<P align="left" style="font-size: 12pt; text-indent: 6%">3.2 <U>FDA Letter</U>. On the Closing Date, or such later date as mutually agreed by the
parties, Mylan shall mail to the FDA the FDA Letter, return receipt requested. Mylan shall provide
Cumberland with proof that FDA received the FDA Letter in the form of a copy of such returned
receipt.


<P align="left" style="font-size: 12pt; text-indent: 6%">3.3 <U>Assumption of Assumed Liabilities</U>. With respect to the purchase and sale of the
Purchased Assets, in addition to the payment of the Royalty, Cumberland shall assume the Assumed
Liabilities on the Closing Date. Cumberland assumes no Excluded Liabilities, and the Parties hereto
agree that all such Excluded Liabilities shall remain the sole responsibility and obligation of
Mylan and/or its Affiliates.


<P align="left" style="font-size: 12pt; text-indent: 6%">3.4 <U>Closing</U>. In the event any of the Transaction Agreements are not delivered as set
forth above and the Closing is not completed, this Agreement and the transactions contemplated
herein shall immediately terminate and no longer be in force or effect.


<P align="center" style="font-size: 12pt"><B>ARTICLE 4<BR>
ROYALTY PAYMENTS</B>



<P align="left" style="font-size: 12pt; text-indent: 6%">4.1 <U>Royalty</U>. In consideration for Sale, assignment, and transfer by Mylan to
Cumberland, of all of Mylan&#146;s rights and interest in and to the Purchased Assets, Cumberland shall
pay Mylan a royalty equal to &#091;***&#093; percent (&#091;***&#093;%) of Net Sales of the Product in the Territory
(the &#147;Royalty&#148;). The payment shall be calculated quarterly and Cumberland shall remit payment to
Mylan within &#091;***&#093; (&#091;***&#093;) days after the end of each calendar &#091;***&#093;, together with a schedule
detailing the calculation. Cumberland shall pay said Royalty for a period of &#091;***&#093; (&#091;***&#093;) years
commencing on the Effective Date.


<P align="left" style="font-size: 12pt; text-indent: 8%">4.1.1. If Net Sales of the Product in the Territory are in excess of &#091;***&#093; U.S. dollars
($&#091;***&#093; USD) in a Year, then Cumberland shall pay Mylan an additional &#091;***&#093; percent (&#091;***&#093;%) for a
total of &#091;***&#093; percent (&#091;***&#093;%) of Net Sales of the Product in the Territory for the subject Year
in excess of $&#091;***&#093;.


<P align="left" style="font-size: 12pt; text-indent: 8%">4.1.2. If Net Sales of the Product in the Territory are in excess of &#091;***&#093; U.S. dollars
($&#091;***&#093; USD) in a Year, then Cumberland shall pay Mylan an additional &#091;***&#093; percent (&#091;***&#093;%) for a
total of &#091;***&#093; percent (&#091;***&#093;%) of Net Sales of the Product in the Territory for the subject Year
in excess of $&#091;***&#093;.


<P align="left" style="font-size: 12pt; text-indent: 5%">4.2 <U>Audit</U>. Cumberland shall maintain complete and accurate books and records with
respect to the determination of Net Sales including, without limitation, such books and records
required to confirm the proper determination of Net Sales. Such books and records shall be
available for inspection and audit by Mylan and/or its designated representatives, subject to
appropriate confidentiality undertakings, and upon reasonable advance notice, at a mutually
agreeable time, during normal business hours. The costs of any such inspection or audit shall be
the responsibility of Mylan unless any such inspection or audit reveals an underpayment of five
percent (5%) or more for any Calendar Quarter in which case such costs will be the responsibility
of Cumberland. Cumberland shall remain responsible for any underpayment disclosed by audit. In the
event that audit reveals an underpayment of five or more percent for three or more Calendar
Quarters during the Term of this Agreement, then Cumberland shall pay Mylan an additional &#091;***&#093;
percent (&#091;***&#093;%) of Net Sales for the period in which such underpayment occurred.


<P align="center" style="font-size: 12pt"><B>ARTICLE 5<BR>
REPRESENTATIONS AND WARRANTIES OF MYLAN</B>



<P align="left" style="font-size: 12pt; text-indent: 6%">Mylan hereby represents and warrants to Cumberland that:


<P align="left" style="font-size: 12pt; text-indent: 6%">5.1 <U>Corporate Organization, Good Standing, Power</U>. Mylan is a corporation duly
organized, validly existing and in good standing under the laws of the Commonwealth of
Pennsylvania. Mylan has the requisite corporate power and authority to execute and deliver the
Transaction Agreements and to consummate the transactions contemplated hereby and thereby, as
applicable, including delivery of the Mylan Deliverables. Each Transaction Agreement, at the
time such agreement is delivered by Mylan, will have been duly executed and delivered by Mylan and
constitutes legal, valid and binding obligations of Mylan, enforceable against Mylan, in accordance
with its terms.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.2 <U>Consents and Approvals; No Conflict</U>. To the best of Mylan&#146;s knowledge and belief,
after due investigation, the execution, delivery and performance by Mylan of the Transaction
Agreements, the delivery of the Mylan Deliverables, and the consummation by Mylan of the
transactions contemplated hereby and thereby will not require any material notice to, material
filing with, or the material consent, approval or authorization of, any Person or Governmental
Authority, except in connection with the FDA Letter and for the transfer of the Product Regulatory
Files. The execution, delivery and performance of the other Transaction Agreements, the delivery
of the Mylan Deliverables, and the consummation of the transactions contemplated hereby and thereby
will not (i)&nbsp;conflict with or result in a breach of any of the provisions of the certificate of
incorporation or by-laws of Mylan, (ii)&nbsp;contravene in any material respect any Applicable Law, or
(iii)&nbsp;subject to Cumberland&#146;s satisfaction as to the Cumberland Waiver, conflict with or result in
a breach of any Third Party agreements or contracts of Mylan or its Affiliates.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.3 <U>Assets</U>. Neither Mylan nor any of its Affiliates owns or controls (including by
joint ownership) any Intellectual Property related to the Product, or necessary for the
Manufacture, use or testing thereof, that is not being sold, assigned, conveyed, transferred and
delivered to Cumberland pursuant to this Agreement. Conditioned upon the successful acquisition by
Mylan of such assets by completing the closing anticipated by the Inalco Asset Purchase Agreement,
Mylan has the sole and exclusive right, title and interest in and to all the Purchased Assets and
the Purchased Assets are free and clear of all Encumbrances.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.4 <U>Litigation</U>. There is no civil, criminal or administrative action, suit, hearing,
or proceeding pending or, to the knowledge of Mylan, after due investigation, threatened against
Mylan or Inalco, or any Affiliate of Mylan or Inalco relating to the Purchased Assets or the
transactions contemplated hereby. There are no outstanding judgments, orders, injunctions, decrees
or awards against Mylan or Inalco in connection with this Agreement or the transactions
contemplated hereby that have not been satisfied in all material respects to the best of Mylan&#146;s
knowledge and belief after due investigation.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.5 <U>Compliance with Laws</U>. To the best of Mylan&#146;s knowledge and belief, after due
investigation, Mylan has been in compliance, in all material respects, with Applicable Laws in
connection with the Purchased Assets. To the knowledge of Mylan, after due investigation, there
are no outstanding material deficiencies in the Product ANDA. Mylan has not received any written
notice from any Governmental Authority that Mylan or its Affiliates, with respect to the Product or
the Purchased Assets, were or are in violation of any Applicable Laws.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.6 <U>Regulatory and FDA Matters</U>. To the best of Mylan&#146;s knowledge and belief, after
due investigation, there is no action or proceeding by the FDA or any other Governmental Authority
concluded, pending or, to the knowledge of Mylan, threatened against Mylan relating to the Product
Regulatory Files or the safety or efficacy of the Product.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.7 <U>Broker&#146;s Fees</U>. Mylan has not employed any broker, finder or investment banker or
incurred any liability for any brokerage, finder&#146;s or other fee or commission in connection with
the transactions contemplated by the Transaction Agreements.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.8 <U>Other Claims.</U> Mylan and its Affiliates have no claims or causes of action against
any Third Party (whether or not such claims or causes of action have been asserted by Mylan)
related to the Purchased Assets, and Mylan possesses no rights of indemnity, warranty rights,
rights of contribution, rights to refund or reimbursements and other rights of recovery possessed
(whether such rights are currently exercisable) related to Product and the Purchased Assets other
than as set forth in this Agreement.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.9 <U>Exclusive Representations and Warranties</U>. Except for the representations and
warranties contained in this Article&nbsp;5 or in any other document or instrument delivered by Mylan
pursuant to this Agreement, neither Mylan nor any other Person makes any other express or implied
representation or warranty on behalf of the Purchased Assets, including any representation or
warranty as to the probable success or profitability of the ownership, use or operation of the
Purchased Assets by Cumberland after the Closing or the value, condition or use of the Purchased
Assets, whether express or implied, including any implied warranty of merchantability or fitness
for a particular purpose.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.10 <U>Debarment Certification</U>. Mylan represents and warrants that neither it nor any
person employed by it to perform any work related to this Agreement (i)&nbsp;is under investigation by
the FDA for debarment action or is presently, has been, or if debarred in the future, will be,
debarred pursuant to Section&nbsp;306 (a)&nbsp;or (b)&nbsp;of the U.S. Generic Drug Enforcement Act of 1992 or
other applicable law or (ii)&nbsp;has a disqualification hearing pending or has been disqualified by the
FDA pursuant to 21 C.F.R. Section&nbsp;312.70. In the event any of the foregoing occurs, Mylan shall
immediately notify Cumberland.


<P align="left" style="font-size: 12pt; text-indent: 6%">5.11 <U>Non Compete</U>. During the period in which Royalty payments are being transferred
by Cumberland to Mylan under section 4.1 herein, Mylan shall neither directly nor indirectly
(through any other Persons, entity or otherwise) without Cumberland&#146;s prior written approval,
promote, sell, market, or distribute in The United States of America, its territories and
possessions, a Competing Product defined as any lactulose crystals product.


<P align="center" style="font-size: 12pt"><B>ARTICLE 6<BR>
REPRESENTATIONS AND WARRANTIES OF CUMBERLAND</B>



<P align="left" style="font-size: 12pt; text-indent: 6%">Cumberland hereby represents and warrants to Mylan that:


<P align="left" style="font-size: 12pt; text-indent: 6%">6.1 <U>Corporate Organization, Good Standing, Power</U>. Cumberland is a corporation duly
organized, validly existing and in good standing under the laws of the State of Tennessee.
Cumberland has the requisite corporate power and authority to execute and deliver the Transaction
Agreements, and to consummate the transactions contemplated hereby and thereby, as applicable,
including delivery of the Cumberland Deliverables and payment of the Royalty. The execution and
delivery by Cumberland of the Transaction Agreements, as applicable, and the consummation by
Cumberland of the transactions contemplated hereby and thereby, as applicable, have been duly
authorized by all necessary corporate action on the part of Cumberland, and no other or further
corporate actions or proceedings will be necessary for the execution and delivery of such
agreements, as applicable, by Cumberland, the performance by Cumberland of its obligations
hereunder and thereunder, as applicable, and the consummation by Cumberland of the transactions
contemplated hereby or thereby, as applicable. Each Transaction Agreement, at the time such
agreement is delivered by Cumberland, will have been duly executed and delivered by Cumberland and
constitutes legal, valid and binding obligations of Cumberland, enforceable against Cumberland in
accordance with its terms.


<P align="left" style="font-size: 12pt; text-indent: 6%">6.2 <U>Consents, No Conflict</U>. The execution, delivery and performance by Cumberland of
the Transaction Agreements, the delivery of the Cumberland Deliverables, and the consummation of
the transactions contemplated hereby and thereby will not require any material notice to, material
filing with, or the material consent, approval or authorization of, any Person, except in
connection with the FDA Letter. The execution and delivery of this Agreement and the other
Transaction Agreement, the delivery of the Cumberland Deliverables and the consummation of the
transactions contemplated hereby and thereby will not (i)&nbsp;conflict with or result in a breach of
any of the provisions of the certificate or articles of incorporation or by-laws of Cumberland,
(ii)&nbsp;contravene in any material respect any Applicable Law, or (iii)&nbsp;conflict with or result in a
breach of any Third Party agreements or contracts of Cumberland or its Affiliates.


<P align="left" style="font-size: 12pt; text-indent: 6%">6.3 <U>Litigation</U>. There is no civil, criminal or administrative action, suit, hearing,
or proceeding pending or, to the knowledge of Cumberland or Mylan, threatened against Cumberland or
any Affiliate of Cumberland or any Affiliate of Mylan relating to the transactions contemplated
hereby. There are no outstanding judgments, orders, injunctions, decrees or awards against
Cumberland or Mylan in connection with this Agreement or the transactions contemplated hereby that
have not been satisfied in all material respects.


<P align="left" style="font-size: 12pt; text-indent: 6%">6.4 <U>Broker&#146;s Fees</U>. Cumberland has not employed any broker, finder or investment
banker or incurred any liability for any brokerage, finder&#146;s or other fee or commission in
connection with the transactions contemplated by the Transaction Agreements.


<P align="left" style="font-size: 12pt; text-indent: 6%">6.5 <U>Exclusive Representations and Warranties</U>. Other than the representations and
warranties set forth in this Article&nbsp;6, Cumberland is not making any other representation or
warranty, express or implied.


<P align="left" style="font-size: 12pt; text-indent: 6%">6.6 <U>Debarment Certification</U>. Cumberland represents and warrants that neither it nor
any person employed by it to perform any work related to this Agreement (i)&nbsp;is under investigation
by the FDA for debarment action or is presently, has been, or if debarred in the future, will be,
debarred pursuant to Section&nbsp;306 (a)&nbsp;or (b)&nbsp;of the U.S. Generic Drug Enforcement Act of 1992 or
other applicable law or (ii)&nbsp;has a disqualification hearing pending or has been disqualified by the
FDA pursuant to 21 C.F.R. Section&nbsp;312.70. In the event any of the foregoing occurs, Cumberland
shall immediately notify Mylan.


<P align="center" style="font-size: 12pt"><B>ARTICLE 7</B><BR>
<U>ADDITIONAL AGREEMENTS</U>



<P align="left" style="font-size: 12pt; text-indent: 6%">7.1 <U>Expenses</U>. Except as specifically set forth in this Agreement, all expenses,
including the fees of any attorneys, accountants, investment bankers or others engaged by a Party,
incurred in connection with the Transaction Agreements and the transactions contemplated hereby and
thereby shall be paid by the Party incurring such expenses, whether or not the transactions
contemplated by the Transaction Agreements are consummated.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.2 <U>Additional Agreements of Mylan.</U> Subject to the terms and conditions herein
provided, Mylan agrees to: (i)&nbsp;do, or cause to be done, all things reasonably necessary or proper
to consummate the transactions contemplated by the Transaction Agreements and to cooperate with
Cumberland in connection with the foregoing; (ii)&nbsp;obtain all necessary consents and approvals (or
effective waiver thereof) from other parties to material agreements, contracts, instruments and
other contracts to consummate the transactions contemplated by the Transaction Agreements; (iii)
effect all necessary registrations and filings and submissions of information required or requested
by Governmental Authorities with respect to the transactions contemplated by the Transaction
Agreements; and (iv)&nbsp;take such actions and provide further assurances reasonably required for
Cumberland to vest more fully in possession of the Purchased Assets. To the extent that Mylan
becomes aware of the Product Regulatory Files not otherwise previously transferred to Cumberland,
Mylan shall promptly notify Cumberland of such and promptly deliver same to Cumberland and the
Product Know-How and Product Regulatory Files shall be deemed to be otherwise included in this
Agreement as of the Closing Date.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.3 <U>Additional Agreements of Cumberland.</U> Subject to the terms and conditions herein
provided, Cumberland agrees to use its commercially reasonable efforts to (i)&nbsp;do, or cause to be
done, all things necessary or proper to consummate the transactions contemplated by the Transaction
Agreements and to cooperate with Mylan in connection with the foregoing, (ii)&nbsp;obtain all necessary
consents and approvals (or effective waivers thereof) from other parties to material agreements,
contracts, instruments and other contracts to consummate the transactions contemplated by the
Transaction Agreements, and (iii)&nbsp;effect all necessary registrations and filings and submissions of
information required or requested by Governmental Authorities with respect to the transactions
contemplated by the Transaction Agreements.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.4 <U>Access to Information</U>. From and after the Closing Date and subject to the terms
hereof, Mylan agrees to cooperate with and to grant to Cumberland and its Representatives, during
normal business hours, reasonable access to its material information and records relating
specifically to the Product and the Product Regulatory Files (including any information underlying
the Product Regulatory Files or data cross-referenced with any pre-clinical, clinical or chemistry,
Manufacturing and control information or data with regard to the Product contained in any other
related Regulatory Files or other regulatory filings or applications of Mylan or its Affiliates
filed with and/or approved by the FDA), but only to the extent such information or records were not
delivered to Cumberland on or after the Closing Date, or continue to be in the possession of
Inalco, for the purposes of (i)&nbsp;gaining Regulatory Approval of the Product ANDA, (ii)&nbsp;any financial
reporting; (iii)&nbsp;defending against any claims or litigation involving the Product or (iv)&nbsp;any
investigation or inquiry being conducted by any federal, state, local or foreign Governmental
Authority involving the Product.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.5 <U>FDA Communications</U>. From and after the Closing Date, except with respect to the
FDA Letter, as required by Applicable Law or as requested by Cumberland, Mylan shall not contact or
communicate with the FDA or any other Governmental Authorities with respect to the Purchased
Assets. Following the Closing Date, Mylan will notify Cumberland of its receipt of any
correspondence from the FDA and, until the parties have delivered to the FDA the FDA Letter, it
will use its commercially reasonable efforts to assist Cumberland in any response to the FDA in
respect thereof.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.6 <U>NDC Numbers</U>. Cumberland hereby acknowledges and agrees that Cumberland shall
assign its own NDC number to the Product.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.7 <U>Records.</U> Cumberland will preserve all books and records included within the
Purchased Assets as required by Applicable Law.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.8 <U>Assumption of Regulatory Commitments</U>. From and after the Closing Date, and
subject to the terms hereof, Cumberland will assume control of, and responsibility for all costs,
obligations and Liabilities arising from or related to, any commitments, requirements or
obligations to, or any requests or orders from, any Governmental Authority involving the Product,
to the extent arising from Product sold by or on behalf of Cumberland or related to the Product
ANDA owned by Cumberland after the Closing Date.


<P align="left" style="font-size: 12pt; text-indent: 6%">7.9 <U>Response to Medical Inquiries and Product Complaints</U>. After the Closing Date,
Cumberland will assume all responsibility for responding to any medical inquiries, adverse event
reports or complaints about the Product in the Territory. Any such inquiries, reports or
complaints received by Mylan shall be promptly forwarded to Cumberland.


<P align="center" style="font-size: 12pt"><B>ARTICLE 8<BR>
INDEMNIFICATION</B>




<P align="left" style="margin-left:2%; font-size: 12pt; text-indent: 4%">8.1 <U>Indemnification.</U>


<P align="left" style="font-size: 12pt; text-indent: 12%">(a)&nbsp;Subject to the provisions of this Article&nbsp;8, Mylan shall indemnify, defend and hold
harmless Cumberland and its officers, directors and employees from any Losses incurred by such
Persons to the extent arising from or attributable to (i)&nbsp;the breach of any representation,
warranty or covenant made by Mylan in this Agreement; or (ii)&nbsp;any Excluded Liability or (iii)&nbsp;the
breach of this Asset Purchase and Royalty Agreement and/or related Transaction Agreements.


<P align="left" style="font-size: 12pt; text-indent: 12%">(b)&nbsp;Subject to the provisions of this Article&nbsp;8, Cumberland shall indemnify, defend and hold
harmless Mylan and its respective officers, directors and employees from any Losses incurred by
such Persons to the extent arising from or attributable to (i)&nbsp;the breach of any representation,
warranty, or covenant made by Cumberland in this Agreement; or (ii)&nbsp;the Assumed Liabilities or
(iii)&nbsp;the breach of this Asset Purchase and Royalty Agreement and/or related Transaction
Agreements.



<P align="left" style="margin-left:2%; font-size: 12pt; text-indent: 4%">8.2 <U>Procedures</U>.


<P align="left" style="font-size: 12pt; text-indent: 12%">(a)&nbsp;Promptly after any Person entitled to indemnity hereunder receives notice or otherwise
becomes aware of any Third Party claim reasonably expected to be formally made against a Party or
the commencement of any Third Party action or proceeding, in each case which may give rise to
indemnification hereunder (a &#147;<U>Claim</U>&#148;), such Person (the &#147;<U>Aggrieved Party</U>&#148;) shall,
if an indemnity claim with respect thereto is to be made against any Party obligated to provide
indemnification pursuant to this Article&nbsp;8 (the &#147;<U>Indemnifying Party</U>&#148;), give such
Indemnifying Party written notice of such claim or the commencement of such action or proceeding or
any of the foregoing; <U>provided</U>, <U>however</U>, that failure to give such notification
will not affect the indemnification provided hereunder except to the extent the Indemnifying Party
shall have been actually prejudiced as a result of such failure. The Indemnifying Party may elect
to assume the defense of any such Claim, or any litigation resulting from such Claim. Upon such
assumption, the Aggrieved Party shall cooperate fully with the Indemnifying Party in the conduct of
such defense. Such duty on the part of the Aggrieved Party to cooperate in such defense shall
include (i)&nbsp;providing assistance in compiling and verifying responses to discovery requests, (ii)
providing reasonable access to its employees for purposes of consulting, performing laboratory
testing, providing deposition and trial testimony and expert opinions and (iii)&nbsp;making available to
the Indemnifying Party all books and records as may have relevance to the defense. The Aggrieved
Party may participate, at its expense (not subject to indemnification hereunder), in the defense of
such Claim; <U>provided</U>, <U>however</U>, that the Indemnifying Party shall direct and control
the defense of such Claim. The Indemnifying Party shall not, in the defense of such Claim, consent
to entry of any judgment or enter into any settlement, except with the written consent of the
Aggrieved Party which, in either case, may not be unreasonably withheld, delayed or conditioned.
In addition, all awards and costs payable by a Third Party to the Aggrieved Party or the
Indemnifying Party shall belong to the Indemnifying Party. The Indemnifying Party shall not be
entitled to control, and the Aggrieved Party shall be entitled to have sole control over, the
defense or settlement of any claim to the extent that such claim seeks any order, injunction or
other equitable relief against the Aggrieved Party.


<P align="left" style="font-size: 12pt; text-indent: 12%">(b)&nbsp;If the Indemnifying Party shall fail to assume the defense of a Claim, the Aggrieved Party
may defend against such Claim in such reasonable manner as it may deem appropriate and the
Aggrieved Party may settle such Claim (but only with the consent of the Indemnifying Party, which
consent shall not be unreasonably withheld, delayed or conditioned) on such terms as it may deem
appropriate, and the Indemnifying Party shall promptly reimburse the Aggrieved Party for the amount
of any indemnifiable Losses incurred by the Aggrieved Party in connection with the defense against
or settlement of such Claim.


<P align="left" style="font-size: 12pt; text-indent: 6%">8.3 <U>Losses</U>. Parties shall take and shall cause their Affiliates to take all
reasonable steps to mitigate any Losses upon becoming aware of any event that would reasonably be
expected to, or does, give rise thereto, including incurring costs only to the minimum extent
necessary to remedy a breach that gives rise to the Loss. If the amount to be netted hereunder
from any payment required under Section&nbsp;8.1 is determined after payment by the Indemnifying Party
of any amount otherwise required to be paid to an Aggrieved Party pursuant to this Article&nbsp;8, the
Aggrieved Party shall repay to the Indemnifying Party, promptly after such determination, any
amount that the Indemnifying Party would not have had to pay pursuant to this Article&nbsp;8 had such
determination been made at the time of such payment.


<P align="center" style="font-size: 12pt"><B>ARTICLE 9<BR>
CONFIDENTIALITY AND PUBLIC DISCLOSURE</B>



<P align="left" style="font-size: 12pt; text-indent: 6%">9.1 The Receiving Party shall not disclose to any Third Party any Confidential Information or
use any such Confidential Information for its own benefit or that of any Third Party without the
written consent of the Disclosing Party. Each Party agrees to protect Confidential Information
received from the other Party at least as well as it would its own proprietary and confidential
information, but using at least a reasonable amount of care.


<P align="left" style="font-size: 12pt; text-indent: 6%">9.2 The Receiving Party shall bind all persons having access through it to any Confidential
Information to comply with the provisions of 8.1. The Receiving Party will be responsible for the
acts of any of its Representatives receiving the Confidential Information.


<P align="left" style="font-size: 12pt; text-indent: 6%">9.3 The Receiving Party, at the request of the Disclosing Party, shall return or destroy all
Confidential Information disclosed to it hereunder, in whatever form contained, including any
listing that identifies the documents provided, except that one copy of all Confidential
Information may be retained at the office of the Receiving Party&#146;s counsel, to maintain a record of
the same.


<P align="left" style="font-size: 12pt; text-indent: 6%">9.4 Notwithstanding anything to the contrary in this Agreement, the Parties understand and
agree that either Party, as the Receiving Party of Confidential Information from the Disclosing
Party, may, if so required, disclose some or all of the information included in this Agreement or
other Confidential Information of the Disclosing Party (i)&nbsp;in order to comply with its obligations
under law, (ii)&nbsp;to respond to an inquiry of a Governmental Authority, or (iii)&nbsp;in a judicial,
administrative or arbitration proceeding. In any such event, the Receiving Party making such
disclosure shall (a)&nbsp;provide the Disclosing Party with as much advance notice as reasonably
practicable of the required disclosure, (b)&nbsp;cooperate with the Disclosing Party in any attempt to
prevent or limit the disclosure, and (c)&nbsp;reasonably limit any disclosure to the specific purpose at
issue. Additionally, each Party shall be free to make comments consistent with any press release
issued in conformance with Section&nbsp;10.1 below.


<P align="center" style="font-size: 12pt"><B>ARTICLE 10<BR>
GENERAL PROVISIONS</B>



<P align="left" style="font-size: 12pt; text-indent: 6%">10.1 <U>Public Statements</U>. With the exception of filings with the Securities and
Exchange Commission, FDA or any other Regulatory Authority, neither Party shall make any publicity
release, interview or make any other dissemination of information concerning this Agreement or its
terms, or the transactions contemplated hereby, to a Third Party without the prior written approval
of the other Party.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.2 <U>Notices</U>. All notices and other communications hereunder shall be in writing and
shall be deemed to have been duly given if delivered personally, mailed by reputable overnight
courier or certified mail (return receipt requested) or sent by facsimile (confirmed thereafter by
such certified mail), to each Party at the following address or at such other address as may be
specified by either Party by like notice:

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD align="left" valign="top">If to Cumberland:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cumberland Pharmaceuticals Inc.<BR>
2525 West End Avenue, Suite&nbsp;950<BR>
Nashville, TN 37203<BR>
Attention: CEO<BR>
Facsimile: (615)&nbsp;255-0094</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD align="left" valign="top">With copies to:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Adams and Reese/Stokes Bartholomew LLP<BR>
424 Church Street, 28<sup>th</sup> Floor<BR>
Nashville, TN 37219<BR>
Attention: Martin S. Brown, Esq.<BR>
Facsimile: (615)&nbsp;259-1470</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD align="left" valign="top">If to Mylan:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mylan Inc.<BR>
1500 Corporate Drive<BR>
Canonsburg, PA 15317<BR>
Attention: NA General Counsel<BR>
Facsimile: (724)&nbsp;514-1972</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD align="left" valign="top">With copies to:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Mylan Inc.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 12pt; text-indent: 19%">1500 Corporate Drive


<P align="left" style="font-size: 12pt; text-indent: 19%">Canonsburg, PA 15317


<P align="left" style="font-size: 12pt; text-indent: 19%">Attention: Global General Counsel


<P align="left" style="font-size: 12pt; text-indent: 19%">Facsimile: (724)&nbsp;514-1972


<P align="left" style="font-size: 12pt; text-indent: 4%">Notice so given shall: (i)&nbsp;in the case of notice so given by personal delivery, be deemed to
be given and received on the date of such personal delivery; (ii)&nbsp;in the case of notice so given by
certified mail, be deemed to be given and received on the third (3<sup>rd</sup>) business day after
mailing; and (iii)&nbsp;in the case of notice so given by a reputable overnight courier, be deemed to be
given and received on the next business day after delivery to such courier.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.3 <U>Amendment</U>. This Agreement may not be amended except by an instrument in writing
signed by each of the Parties.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.4 <U>Waiver</U>. Any term, provision or condition of this Agreement may be waived (or the
time for performance of any of the obligations or other acts of any Party may be extended) only if
in writing and signed by the Party that is entitled to the benefit of such term, provision or
condition.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.5 <U>Parties in Interest</U>. Other than in connection with a merger, consolidation or
similar reorganization, or sale of all or substantially all of its assets, no Party may delegate
its duties under this Agreement without the consent of the other Party hereto, which consent shall
not be unreasonably withheld. No Party may assign its rights under this Agreement without the
consent of the other Parties hereto, which consent shall not be unreasonably withheld. This
Agreement shall not run to the benefit of or be enforceable by any Person other than a Party to
this Agreement and, subject to this Section&nbsp;10.5, its successors and permitted assigns. Any
assignment of this Agreement in contravention of this Section&nbsp;10.5 shall be null and void <I>ab
initio</I>.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.6 <U>Entire Agreement</U>. This Agreement (including the documents and instruments
referred to herein) and the other Transaction Agreement, constitutes the entire agreement and
supersedes all other prior agreements and undertakings, both written and oral, between the Parties,
with respect to the subject matter hereof.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.7 <U>Governing Law; Jurisdiction</U>. The Transaction Agreements shall be governed in all
respects, including validity, interpretation and effect, by the internal laws of the State of New
York, without regard to the conflicts of law provisions thereof with the exception of Sections
5-1401 and 5-1402 of the New York General Obligations Law. The Parties agree that the U.S.
District Court for the Southern District of New York shall have exclusive jurisdiction over any
dispute or controversy arising out of or relating to this Agreement and any judgment,
determination, arbitration award, finding or conclusion reached or rendered in any other
jurisdiction shall be null and void between the Parties. Each of the Parties waives any defense of
inconvenient forum to the maintenance of any action or proceeding so brought and waives any right
to trial by jury in any action, proceeding or counterclaim arising out of or relating to this
Agreement, the transactions contemplated hereby or the actions of Parties in the negotiation,
administration, performance and enforcement hereof.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.8 <U>Counterparts</U>. This Agreement may be executed and delivered in two or more
counterparts, each of which shall for all purposes be deemed to be an original and all of which
shall constitute on instrument. Electronically transmitted signature copies shall be binding on the
Parties as originals.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.9 <U>Third Party Beneficiaries</U>. Except as set forth in 8.1(a) and (b), no term or
provision of this Agreement is intended to be, or shall be, for the benefit of any Person other
than the Parties, and no such other Person shall have any right or cause of action hereunder.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.10 <U>Validity</U>. If any provisions of this Agreement shall be held to be illegal,
invalid or unenforceable under any Applicable Law, then such contravention or invalidity shall not
invalidate the entire Agreement. Such provision shall be deemed to be modified to the extent
necessary to render it legal, valid and enforceable, and if no such modification shall render it
legal, valid and enforceable, then this Agreement shall be construed as if not containing the
provision held to be invalid, and the rights and obligations of the Parties shall be construed and
enforced accordingly.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.11 <U>Conditions.</U> The validity of his Agreement is conditioned upon the successful
acquisition by Mylan of such assets by completing the closing anticipated by the Inalco Asset
Purchase Agreement.


<P align="left" style="font-size: 12pt; text-indent: 6%">10.12 <U>Survival.</U> The representations and warranties of each Party contained herein
shall survive until the seventh (7<sup>th</sup>) anniversary of the Closing of this Agreement.


<P align="center" style="font-size: 12pt"><B>SIGNATURE PAGE TO FOLLOW</B>




<P align="center" style="font-size: 10pt; display: none">1
<!-- PAGEBREAK -->




<P align="center" style="font-size: 12pt"><B>IN WITNESS WHEREOF</B>, the Parties hereto, intending to be legally bound, have caused this Asset<BR>
Purchase and Royalty Agreement to be executed as of the date first written above.


<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="43%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="52%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">MYLAN INC.<BR>
By: /s/ John Deiniggi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND PHARMACEUTICALS INC.<BR>
By: /s/ A.J. Kazimi</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Print Name: John Deiniggi
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Print Name: A.J. Kazimi</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title: SVP, NA Operations
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Chief Executive Officer</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt; display: none">2
<!-- PAGEBREAK -->


<P align="center" style="font-size: 12pt"><B>EXHIBIT A<BR>
GENERAL ASSIGNMENT AND BILL OF SALE</B>



<P align="left" style="font-size: 12pt"><B>THIS GENERAL ASSIGNMENT AND BILL OF SALE </B>(this &#147;General Assignment&#148;) dated as of the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2011 (the &#147;Closing Date&#148;), by and among Mylan Inc., a Pennsylvania corporation
located at 1500 Corporate Drive, Canonsburg, Pennsylvania 15317 (&#147;Seller&#148;) and Cumberland
Pharmaceuticals Inc., a corporation organized under the laws of the State of Tennessee with a place
of business at 2525 West End Avenue, Suite&nbsp;950, Nashville, Tennessee, USA 37203 (hereinafter
referred to as &#147;Buyer&#148;). Seller and Buyer may each be referred to herein individually as a &#147;Party&#148;
and collectively as the &#147;Parties&#148;.


<P align="left" style="font-size: 12pt; text-indent: 4%"><B>WHEREAS</B>, Seller and Buyer are Parties to that certain Asset Purchase and Royalty Agreement
with an Effective Date of the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2011 (the &#147;Asset Purchase Agreement&#148;), pursuant
to which certain assets and liabilities of Seller are to be transferred to, and assumed by, the
Buyer;


<P align="left" style="font-size: 12pt; text-indent: 4%"><B>WHEREAS</B>, in performance of their respective obligations under the Asset Purchase and Royalty
Agreement, Seller and Buyer desire to execute and deliver this General Assignment;


<P align="left" style="font-size: 12pt; text-indent: 4%"><B>NOW, THEREFORE</B>, for and in consideration of the foregoing premises and the mutual covenants
contained herein, and for other good and valuable consideration, the receipt and legal sufficiency
of which are hereby acknowledged, the Parties do hereby agree as follows:


<P align="left" style="font-size: 12pt">1.&nbsp;Capitalized terms used but not defined herein shall have the meanings for such terms that are
set forth in the Asset Purchase and Royalty Agreement.


<P align="left" style="font-size: 12pt">2.&nbsp;Seller does hereby sell, assign, convey, grant and transfer unto Buyer to have and to hold
forever, the Purchased Assets including, without limitation, all of Seller&#146;s right, title and
interest, of every nature and description, in and to the Purchased Assets, wherever located.


<P align="left" style="font-size: 12pt">3.&nbsp;Seller does hereby assign, sell, and transfer (collectively, the &#147;<U>Assignment</U>&#148;) to Buyer,
all of Seller&#146;s right, title, benefit, privileges and interest in and to, and all of Seller&#146;s
burdens, obligations and liabilities in connection with, each of the Assumed Liabilities.


<P align="left" style="font-size: 12pt">4.&nbsp;Buyer does hereby accept the Assignment and assumes and agrees to observe and perform such
duties, responsibilities, obligations, terms, provisions and covenants, and to pay and discharge
such liabilities of Seller to be observed, performed, paid or discharged from and after the Closing
Date, in connection with the Assumed Liabilities. Buyer assumes no Excluded Liabilities, and the
Parties hereto agree that all such Excluded Liabilities shall remain the sole responsibility of
Seller.


<P align="left" style="font-size: 12pt">5.&nbsp;This General Assignment shall inure to the benefit of, and be binding upon, the Parties hereto
and their respective heirs, successors, trustees, transferee and assigns.


<P align="left" style="font-size: 12pt">6.&nbsp;This General Assignment is executed by the Parties and shall be binding upon each Party and its
successors and assigns, for the uses and purposes set forth above and referred to herein, effective
immediately upon its execution by the Parties.


<P align="left" style="font-size: 12pt">7.&nbsp;Each of the Parties hereto covenants and agrees, at its own expense and without further
consideration, to acknowledge, execute and deliver, at the request of the other Party hereto, all
such further instruments of transfer, conveyance, and/or assignment and to take such other action
as such other Party may reasonably request to effectuate the provisions set forth in the General
Assignment to Buyer.


<P align="left" style="font-size: 12pt">8.&nbsp;In the event of any conflict or inconsistency between the terms of the Acquisition Agreement and
the terms hereof, the terms of the Acquisition Agreement shall govern.


<P align="left" style="font-size: 12pt">9.&nbsp;This General Assignment may be executed in one or more counterparts, each of which shall for all
purposes are deemed to be an original and all of which shall constitute one and the same
instrument. Electronically transmitted signature copies shall be binding on the Parties as
originals.


<P align="left" style="font-size: 12pt; text-indent: 4%"><B>IN WITNESS WHEREOF</B>, the Parties hereto have each caused this General Assignment and Bill of
Sale to be duly executed as of the date first above written.

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">MYLAN INC.<BR>
By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND PHARMACEUTICALS INC.<BR>
By:</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Print Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Print Name:</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt; display: none">3
<!-- PAGEBREAK -->


<P align="center" style="font-size: 12pt"><B>EXHIBIT B<BR>
FDA LETTER</B>



<P align="left" style="font-size: 12pt"><B>&#091;insert date&#093;</B>


<P align="left" style="font-size: 12pt"><B>VIA FACSIMILE AND FEDERAL EXPRESS</B>


<P align="left" style="font-size: 12pt">Gary Buehler, Director
<BR>
Office of Generic Drugs
<BR>
Center for Drug Evaluation and Research
<BR>
Food and Drug Administration
<BR>
Document Control Room
<BR>
Metro Park North II
<BR>
7500 Standish Place, Room&nbsp;E-150
<BR>
Rockville, MD 20855-2773

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="37%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
</TR>
<TR style="font-size: 12pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>General Correspondence:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="5"><B>Change of Abbreviated New Drug</B></TD>
</TR>
<TR style="font-size: 12pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="5"><B>Application (&#147;ANDA&#148;) Ownership</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" nowrap valign="top" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ANDA Number:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">074712</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#091;insert title&#093;</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 12pt">Dear Dr.&nbsp;Buehler:


<P align="left" style="font-size: 12pt">The purpose of this correspondence is to notify the FDA pursuant to 21 C.F.R. &#167;314.72 that, on
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2011, Mylan Inc. (&#147;<U>Mylan</U>&#148;) assigned and transferred to Cumberland Inc.
(&#147;<U>Cumberland</U>&#148;) all of Mylan&#146;s rights, title and interest to the above referenced ANDA, and
that Cumberland, effective on such date, is now the owner of such ANDA. All documentation Mylan
possessed relevant to the ANDA, including a complete copy of the ANDA and all supplements,
amendments, correspondence and records, have been provided to Cumberland.


<P align="left" style="font-size: 12pt">The contact information for Cumberland is as follows:

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="100%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Name:</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Contact Name:</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telephone:</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax:</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Email:</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 12pt">Please do not hesitate to contact me with any questions you may have concerning this correspondence
via telephone at <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> or email at <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.


<P align="left" style="font-size: 12pt">Sincerely,


<P align="left" style="font-size: 12pt"><B>&#091;insert name&#093;</B>
<BR>
<B>&#091;insert title&#093;</B>


<P align="left" style="font-size: 12pt">CC:
<BR>
<B>&#091;insert name&#093;</B>
<BR>
<B>&#091;insert title&#093;</B>


<P align="center" style="font-size: 10pt; display: none">4
<!-- PAGEBREAK -->

<P align="center" style="font-size: 12pt"><B>EXHIBIT C</B>



<P align="center" style="font-size: 12pt"><B>TRADEMARK ASSIGNMENT AGREEMENT &#150; 2011</B>



<P align="left" style="font-size: 12pt"><B>This Trademark </B>Assignment (&#147;Assignment&#148;) is made and entered into as of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
<BR>
2011, by and between Mylan Inc., a Pennsylvania corporation located at 1500 Corporate Drive,
Canonsburg, Pennsylvania 15317 (&#147;Assignor&#148;) and Cumberland Pharmaceuticals Inc., a corporation
organized under the laws of the State of Tennessee with a place of business at 2525 West End
Avenue, Suite&nbsp;950, Nashville, Tennessee, USA 37203 (hereinafter referred to as &#147;Assignee&#148;).
Assignor and Assignee are sometimes referred to collectively herein as the &#147;Parties&#148; and
individually as a &#147;Party&#148;.


<P align="left" style="font-size: 12pt">WHEREAS, the Parties have executed an Asset Purchase and Royalty Agreement to which this Assignment
is referenced and attached;


<P align="left" style="font-size: 12pt">WHEREAS, Assignor is the owner of all right, title and interest in and to the United
<BR>
States Registered Trademark KRISTALOSE, Registration No.&nbsp;2,439,494 (the &#147;Trademark&#148; or
&#147;Registration&#148;), together with the goodwill of the business connected with and symbolized by the
Trademark; and


<P align="left" style="font-size: 12pt">WHEREAS, Assignee desires to acquire all right, title and interest in and to the Trademark.


<P align="left" style="font-size: 12pt">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
acknowledged, the parties hereby agree as set forth below.


<P align="left" style="font-size: 12pt">Assignor hereby sells, assigns, transfers and conveys to Assignee the entire right, title,
<BR>
interest in and to the Trademarks in the United States, together with the goodwill of the business
connected with and symbolized by the Trademark (including, without limitation, the right to renew
any registrations included in the Trademark, the right to apply for trademark registrations within
or outside the United States based in whole or in part upon the Trademark, and any priority right
that may arise from the Trademark), and the right to sue for and collect damages for infringements
or other violations of the same, including for past infringements or violations, </FONT><FONT style="font-size: 10pt"> </FONT><FONT style="font-size: 12pt">the
same to be held and enjoyed by Assignee as fully and entirely as said interest could have been held
and enjoyed by Assignor had this sale, assignment, transfer and conveyance not been made.
</FONT>

<P align="left" style="font-size: 12pt">Assignor authorizes the Commissioner of Trademarks of the United States and other empowered
officials of the United States Patent and Trademark Office to record the transfer of the
Registration to Assignee as assignee of Assignor&#146;s entire right, title and interest therein.


<P align="left" style="font-size: 12pt">Assignor agrees to further execute any documents reasonably necessary to effect this assignment or
to confirm Assignee&#146;s ownership of the Trademarks.


<P align="left" style="font-size: 12pt">This Trademark Assignment Agreement may be executed by the Parties hereto in separate counterparts,
each of which when so executed and delivered shall be an original, but all such counterparts taken
together shall constitute one and the same instrument. Electronically transmitted signature copies
shall be binding on the Parties as originals.


<P align="left" style="font-size: 12pt">IN WITNESS WHEREOF, the parties hereto have executed this Trademark Assignment
<BR>
Agreement as of the date first written above.

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="26%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">MYLAN INC.<BR>
By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CUMBERLAND PHARMACEUTICALS INC.<BR>
By:</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Print Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Print Name:</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt; display: none">5




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
